- Home
- BCLI vs JAGX Comparison
BCLI vs JAGX Comparison
Compare BCLI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- JAGX
- Stock Information
- Founded
- BCLI 2000
- JAGX 2013
- Country
- BCLI United States
- JAGX United States
- Employees
- BCLI N/A
- JAGX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- JAGX Health Care
- Exchange
- BCLI Nasdaq
- JAGX Nasdaq
- Market Cap
- BCLI 9.9M
- JAGX 12.9M
- IPO Year
- BCLI N/A
- JAGX N/A
- Fundamental
- Price
- BCLI $1.73
- JAGX $0.86
- Analyst Decision
- BCLI Strong Buy
- JAGX
- Analyst Count
- BCLI 1
- JAGX 0
- Target Price
- BCLI $30.00
- JAGX N/A
- AVG Volume (30 Days)
- BCLI 41.1K
- JAGX 311.0K
- Earning Date
- BCLI 03-31-2025
- JAGX 03-31-2025
- Dividend Yield
- BCLI N/A
- JAGX N/A
- EPS Growth
- BCLI N/A
- JAGX N/A
- EPS
- BCLI N/A
- JAGX N/A
- Revenue
- BCLI N/A
- JAGX $10,480,000.00
- Revenue This Year
- BCLI N/A
- JAGX $18.18
- Revenue Next Year
- BCLI N/A
- JAGX $40.06
- P/E Ratio
- BCLI N/A
- JAGX N/A
- Revenue Growth
- BCLI N/A
- JAGX N/A
- 52 Week Low
- BCLI $1.05
- JAGX $0.78
- 52 Week High
- BCLI $11.85
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- BCLI 40.62
- JAGX 45.91
- Support Level
- BCLI $1.69
- JAGX $0.78
- Resistance Level
- BCLI $1.93
- JAGX $1.03
- Average True Range (ATR)
- BCLI 0.11
- JAGX 0.07
- MACD
- BCLI -0.00
- JAGX 0.01
- Stochastic Oscillator
- BCLI 16.67
- JAGX 30.44
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.